title: [Use of octreotide in the treatment of digestive endocrine tumors. A French multicenter study].
abstract: Morbidity and mortality in endocrine gastro-enteropancreatic (GEP) tumours are mainly related to the clinical consequences of tumoral peptide hypersecretion. Surgical resection at an early stage is the only curative treatment. However, most tumours are detected only when the hypersecretory state reflects the presence of metastases; surgery and chemotherapy then give only palliative results counterbalanced by serious side-effects. Somatostatin inhibits most endocrine secretions of the GEP tract and thus can alleviate invalidating symptoms. Its use is limited by its short half-life (2 min), the necessity of i.v. infusion and the possibility of a rebound phenomenon. Octreotide, a synthetic somatostatin analogue with a long duration of action, is administered subcutaneously and allows ambulatory treatment. In our series of 78 patients we observed about 80 percent of excellent or good clinical results, enabling the patients to resume normal life. Only minor and transient side-effects were noted. The overall tolerance of the drug was considered excellent or good. Prolonged administration of octreotide is a safe and effective symptomatic treatment in patients without any restriction of anti-tumoral procedures. Furthermore, it prevents the severe carcinoid crises that occur during surgery or embolization in patients with carcinoid syndromes.
authors.affiliation: Laboratoires Sandoz, Rueil-Malmaison.
authors.forename: M
authors.initials: M
authors.lastname: Blanchin
authors.forename: A
authors.initials: A
authors.lastname: James-Deidier
authors.forename: P D
authors.initials: PD
authors.lastname: Chaumet-Riffaud
authors.forename: J A
authors.initials: JA
authors.lastname: Chayvialle
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005602:France; D015408:Gastrinoma / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D005935:Glucagonoma / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000652:urine; D007231:Infant, Newborn; D007279:Injections, Subcutaneous; D007340:Insulinoma / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D008297:Male; D008875:Middle Aged; D009377:Multiple Endocrine Neoplasia / Q000097:blood / Q000188:drug therapy / Q000652:urine; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D010182:Pancreatic Diseases / Q000188:drug therapy; D010190:Pancreatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D012701:Serotonin / Q000097:blood; D003969:Vipoma / Q000097:blood / Q000188:drug therapy / Q000652:urine
chemical_list: D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D015282:Octreotide